Industry news that matters to you.  Learn more

Archives for December 2014

PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules

PDI, Inc. (Nasdaq: PDII) recently announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.  Over 525,000 thyroid FNA’s (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate.  ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.

KineMed Receives Grant to Apply Novel Method for Measuring Muscle Mass in Infants and Children for the Diagnosis and Prevention of Malnutrition and Growth Stunting

KineMed, Inc. (www.kinemed.com) recently announced that it has been awarded a three-year grant by the Bill & Melinda Gates Foundation to apply its novel, proprietary non-invasive measurement of skeletal muscle mass to pre-term and full-term infants and young children. The Principal Investigator, William Evans, Ph.D., is head of the KineMed Division of Muscle and Health. The study will, for the first time, measure changes in skeletal muscle mass during one year of growth. The information from this project will provide new information to better assess the effects of nutritional status and other factors that result in the loss of muscle.

Oncotype DX DCIS Score Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer

Genomic Health, Inc. (Nasdaq: GHDX) recently announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score™ is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p<0.001).

Halozyme Announces Presentations of Preclinical Data at the San Antonio Breast Cancer Symposium Annual Meeting

Halozyme Therapeutics, Inc.(NASDAQ: HALO) recently announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS). The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.

KineMed Biomarker Studies in Chronic Lymphocytic Leukemia Reveal Groundbreaking Approach for Guiding Patient Management and Drug Development

KineMed, Inc. recently announced that two Chronic Lymphocytic Leukemia (CLL) studies utilizing KineMed’s proprietary kinetic biomarker technology, will be presented at the American Society of Hematology Annual Meeting taking place this weekend in San Francisco, California. KineMed’s CLL research collaborators, Jan A. Burger, MD, Ph.D., of the MD Anderson Cancer Center, and Elizabeth J. Murphy, MD, DPhil, from the at the University of California San Francisco Department of Medicine and representing the CLL Research Consortium investigators, will present the studies at the conference.